Eloxx doses first patients in Phase 2b Alport syndrome trial

September 11, 2026 7:30 AM

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) announced that the first two patients have been dosed in the EXACT Study, a Phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found